Par's Megace ES Clears FDA; Company Will Target Generic Megestrol Users
This article was originally published in The Pink Sheet Daily
Executive Summary
Concentrated version of the appetite stimulant megestrol acetate oral suspension will launch the week of July 11 through Par's 59-rep sales force. The company expects to convert half the $60 mil. generic market for megestrol acetate oral suspension to Megace ES by the end of 2006.